Yuki Takamatsu

9PUBLICATIONS
39CO-AUTHORS
Biologically active moleculesCheminformatics and quantitative structure-activity relationshipsInnate immunityInfectious diseasesRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 20, 2025
An orally available P1'-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier.

Nobuyo Higashi-Kuwata, Haydar Bulut, Hironori Hayashi

|Feb 25, 2023
Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2.

Nobuyo Higashi-Kuwata, Kohei Tsuji, Hironori Hayashi

|Oct 11, 2022
SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.

Yuki Takamatsu, Kazumi Omata, Yosuke Shimizu

|Nov 24, 2021
Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.

Yuki Takamatsu, Masaki Imai, Kenji Maeda

|Jan 29, 2021
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.

Shin-Ichiro Hattori, Nobuyo Higashi-Kuwata, Hironori Hayashi

|Aug 22, 2020
GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.

Shin-Ichiro Hattori, Nobuyo Higshi-Kuwata, Jakka Raghavaiah

Pageof 2

Frequent Collaborators

8 joint publications

Hiroaki Mitsuya

4 joint publications

Debananda Das

4 joint publications

Haydar Bulut

3 joint publications

Yoshihiro Kawaoka